FDA Approves Hympavzi for Hemophilia A and B

52 Views

Emedinexus 10 May 2025

The FDA has approved Hympavzi for preventing or reducing bleeding episodes in patients 12 and older with hemophilia A or B, provided they lack specific factor inhibitors. This new option offers hope for better bleed management in those with hemophilia.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.